rs3804158
Variant names: 
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001361665.2(FGF2):c.*1349G>A variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.413 in 152,096 control chromosomes in the GnomAD database, including 15,851 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: 𝑓 0.41   (  15846   hom.,  cov: 33) 
 Exomes 𝑓:  0.44   (  5   hom.  ) 
Consequence
 FGF2
NM_001361665.2 3_prime_UTR
NM_001361665.2 3_prime_UTR
Scores
 2
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  -0.190  
Publications
19 publications found 
Genes affected
 FGF2  (HGNC:3676):  (fibroblast growth factor 2) The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008] 
 NUDT6  (HGNC:8053):  (nudix hydrolase 6) This gene overlaps and lies on the opposite strand from FGF2 gene, and is thought to be the FGF2 antisense gene. The two genes are independently transcribed, and their expression shows an inverse relationship, suggesting that this antisense transcript may regulate FGF2 expression. This gene has also been shown to have hormone-regulatory and antiproliferative actions in the pituitary that are independent of FGF2 expression. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011] 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91). 
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.552  is higher than 0.05. 
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| FGF2 | NM_001361665.2  | c.*1349G>A | 3_prime_UTR_variant | Exon 3 of 3 | ENST00000644866.2 | NP_001348594.1 | ||
| NUDT6 | NM_007083.5  | c.554-520C>T | intron_variant | Intron 4 of 4 | ENST00000304430.10 | NP_009014.2 | ||
| FGF2 | NM_002006.6  | c.*1349G>A | 3_prime_UTR_variant | Exon 3 of 3 | NP_001997.5 | |||
| NUDT6 | NM_198041.3  | c.47-520C>T | intron_variant | Intron 4 of 4 | NP_932158.1 | 
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.413  AC: 62737AN: 151942Hom.:  15840  Cov.: 33 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
62737
AN: 
151942
Hom.: 
Cov.: 
33
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD4 exome  AF:  0.444  AC: 16AN: 36Hom.:  5  Cov.: 0 AF XY:  0.563  AC XY: 9AN XY: 16 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
16
AN: 
36
Hom.: 
Cov.: 
0
 AF XY: 
AC XY: 
9
AN XY: 
16
show subpopulations 
African (AFR) 
AC: 
0
AN: 
0
American (AMR) 
AC: 
0
AN: 
0
Ashkenazi Jewish (ASJ) 
AC: 
0
AN: 
0
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
2
South Asian (SAS) 
 AF: 
AC: 
1
AN: 
2
European-Finnish (FIN) 
 AF: 
AC: 
3
AN: 
4
Middle Eastern (MID) 
AC: 
0
AN: 
0
European-Non Finnish (NFE) 
 AF: 
AC: 
11
AN: 
26
Other (OTH) 
 AF: 
AC: 
1
AN: 
2
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.492 
Heterozygous variant carriers
 0 
 1 
 1 
 2 
 2 
 3 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Hom
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome   AF:  0.413  AC: 62747AN: 152060Hom.:  15846  Cov.: 33 AF XY:  0.410  AC XY: 30484AN XY: 74308 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
62747
AN: 
152060
Hom.: 
Cov.: 
33
 AF XY: 
AC XY: 
30484
AN XY: 
74308
show subpopulations 
African (AFR) 
 AF: 
AC: 
4612
AN: 
41508
American (AMR) 
 AF: 
AC: 
7335
AN: 
15274
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
1583
AN: 
3468
East Asian (EAS) 
 AF: 
AC: 
2337
AN: 
5174
South Asian (SAS) 
 AF: 
AC: 
1211
AN: 
4822
European-Finnish (FIN) 
 AF: 
AC: 
6275
AN: 
10538
Middle Eastern (MID) 
 AF: 
AC: 
86
AN: 
292
European-Non Finnish (NFE) 
 AF: 
AC: 
37822
AN: 
67960
Other (OTH) 
 AF: 
AC: 
931
AN: 
2112
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.503 
Heterozygous variant carriers
 0 
 1623 
 3246 
 4869 
 6492 
 8115 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 556 
 1112 
 1668 
 2224 
 2780 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
1246
AN: 
3478
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.